StreetInsider.com News Articles

Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy

Mon, 28 Sep 2026 06:30:00 -0400

SAN FRANCISCO and SUZHOU, China, Sept. 28, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, announced that the China National Medical Products Administration (NMPA) has approved Jaypirca^® (pirtobrutinib, 100 mg & 50 mg tablets), a non-covalent Bruton tyrosine kinase (BTK) inhibitor, as a monotherapy for the treatment of adult patient with

Jaypirca® (pirtobrutinib) Approved in China for a New Indication in Chronic Lymphocytic Leukemia (CLL) /Small Lymphocytic Lymphoma (SLL) Across All Lines of Therapy

Mon, 28 Sep 2026 06:30:00 -0400

Innovent expands Phase 3 lung cancer trial to non-squamous NSCLC

Sun, 27 Sep 2026 20:00:13 -0400

Innovent Biologics (HKEX: 01801) announced the expansion of its global Phase 3 MarsLight-11 clinical trial (NCT07217301) to include patients with non-squamous non-small cell lung cancer (NSCLC), adding a second substudy to the ongoing trial, according to a press release dated Sept. 27, 2026.

The trial evaluates IBI363, also known as TAK-928, a drug candidate described as a potential first-in-class alpha-biased IL-2/PD-1 bispecific fusion protein, which is being co-developed by Innovent and Takeda. The original MarsLight-11 study enrolled patients with squamous NSCLC whose disease had progressed on or after chemotherapy and immunotherapy.

The expanded trial will now comprise two independent substudies — one

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ

Sun, 27 Sep 2026 20:00:00 -0400

SAN FRANCISCO and SUZHOU, China, Sept. 27, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative drugs for major diseases including oncology, autoimmune, metabolic, and ophthalmic diseases, announces expansion of the global Phase 3 MarsLight-11 (NCT07217301) trial, which is evaluating IBI363 (Takeda R&D code: TAK-928) in patients with squamous non-small cell lung cancer (NSCLC) whose disease has progressed on or after chemotherapy and immunotherapy,

Innovent Announces Expansion of Global Phase 3 MarsLight-11 Study of IBI363/TAK-928 (Alpha-biased IL-2/PD-1 Bispecific Fusion Protein) in Immunotherapy-Resistant NSCLC to Include Patients with Non-Squ

Sun, 27 Sep 2026 20:00:00 -0400

Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting

Wed, 23 Sep 2026 04:48:00 -0400

SAN FRANCISCO and SUZHOU, China, Sept. 23, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, announces that clinical data for its IBI363/TAK-928 (PD-1/IL-2^α-biased bispecific fusion protein)^* , IBI343/TAK-921 (Arcotatug Tavetecan, CLDN18.2 ADC)^*, IBI3001(EGFR/B7H3 ADC)^* , IBI354(HER2 ADC) and TYVYT® (sintilimab injection)^** will be presented

Innovent to Present New Clinical Data of Next-gen IO and ADC Pipeline at the 2026 ESMO Annual Meeting

Wed, 23 Sep 2026 04:48:00 -0400

Innovent Announces 2026 Interim Results and Business Updates